Health Care • Misc Health and Biotechnology Services
$9.95 ▼ -0.04
(-0.40%)
MKT CAP: $379.0M • VOL: 227.3K
52W L $6 52W H $13
VMD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $270.3M | $224.3M | $183.0M |
| YoY Revenue Growth % | +20.5% | +22.5% | — |
| Gross Profit | $155.5M | $133.2M | — |
| Gross Margin % | 57.5% | 59.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $22.9M | $17.9M | $14.3M |
| Operating Margin % | 8.5% | 8.0% | 7.8% |
| Net Income (GAAP) | $15.4M | $11.4M | $10.2M |
| EBITDA (Normalized) | $54.9M | $48.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $51.9M | $39.1M | $45.2M |
| Capital Expenditures (CapEx) | $40.0M | $37.8M | — |
| Free Cash Flow (FCF) | $11.9M | $1.3M | $45.2M |
| FCF Margin % | 4.4% | 0.6% | 24.7% |
| Return on Invested Capital (ROIC %) | 13.0% | 12.0% | — |
| Cash & Short-Term Equivalents | $13.5M | $17.5M | — |
| Total Debt (Short + Long Term) | $11.3M | $3.6M | — |
| Total Stockholders' Equity | $141.5M | $131.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR VMD.